Abstract
The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 487-494 |
| Number of pages | 8 |
| Journal | Current Opinion in Drug Discovery and Development |
| Volume | 8 |
| Issue number | 4 |
| State | Published - Jul 1 2005 |
Keywords
- ADME
- High-throughput screening
- Lead discovery
- Medicinal chemistry
- Toxicology
- Virtual screening
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery